Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSC-AAT
- Development stage
- Unknown
- Lead developer
- Kyttaro
- Modality
- Gene Addition/Replacement → Gene Therapies, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Parenteral
01
Overview
MSC-AAT is a genetically engineered cell therapy platform consisting of mesenchymal stem cells (MSCs) modified to overexpress alpha-1 antitrypsin (AAT). Developed by Kyttaro Therapeutics (and associated with Exollent Therapeutics), this candidate leverages the innate immunomodulatory and regenerative properties of MSCs alongside the potent anti-inflammatory and cytoprotective effects of AAT. AAT is a serine protease inhibitor that protects tissues from proteolytic damage and modulates immune responses by promoting the expansion and function of regulatory T cells (Tregs) and regulatory B cells, while suppressing pro-inflammatory Th1 and Th17 responses. The therapy is primarily being investigated for the treatment of Graft-versus-Host Disease (GvHD), Type 1 Diabetes, and various inflammatory lung and joint diseases, aiming to induce immune tolerance and protect target tissues from autoimmune destruction.
- Other names
- AAT-MSCsalpha-1 antitrypsin-expressing mesenchymal stem cellsalpha1 antitrypsin-expressing mesenchymal stem cellsalpha 1 antitrypsin-expressing mesenchymal stem cellsAAT-overexpressing MSCs
Beyond the preview
Go deeper on MSC-AAT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSC-AAT.